Target intelligence / Profile preview

Transmembrane protein 86B (TMEM86B)

Target
TMEM86B
Molecular classification
Enzyme (hydrolase), Transmembrane protein, YhhN family protein
01

Overview

Transmembrane protein 86B (TMEM86B) is a membrane-bound hydrolase that serves as the major lysoplasmalogenase in mammals, catalyzing the cleavage of the vinyl ether bond in lysoplasmalogens to generate fatty aldehydes and glycerophosphocholine or glycerophosphoethanolamine. It is part of the YhhN protein family and is highly expressed in the liver, with lower expression in other tissues including duodenum and brain. TMEM86B plays a central role in ether lipid metabolism and the regulation of cellular plasmalogen levels, making it relevant to inherited and acquired diseases of lipid metabolism. Dysregulation may contribute to disorders like rhizomelic chondrodysplasia punctata and retinal degeneration conditions. No drugs currently target TMEM86B directly; however, its enzymatic activity and the resulting lipid species are important for understanding cellular lipid balance and related pathologies.

Other names
Lysoplasmalogenase TMEM86BAlkenylglycerophosphocholine hydrolaseAlkenylglycerophosphoethanolamine hydrolaseMGC30208TMEM86BTransmembrane protein 86BLysoplasmalogenase
02

Mechanism of action

Not established in humans; inhibition or modulation may affect plasmalogen levels, which could be exploited therapeutically in disorders of lipid metabolism.

03

Biological functions

Ether lipid metabolismHydrolysis of vinyl ether bonds in lysoplasmalogensRegulation of plasmalogen levelsPhospholipid metabolism
04

Disease associations

Rhizomelic chondrodysplasia punctataLeber congenital amaurosisOther disorders of ether lipid metabolismPotential roles in diseases with altered plasmalogen homeostasis (e.g., neurological, metabolic, or cardiovascular)
05

Safety considerations

Therapeutic targeting may disrupt membrane lipid homeostasis, which is crucial for cellular function in organs with high plasmalogen content (e.g., brain, heart, liver)No reported clinical safety issues due to lack of targeted therapy.
06

Biomarkers

Plasmalogen levels and ether lipid species in cells/tissues may be considered biomarkers for TMEM86B function or inhibition

Beyond the preview

Go deeper on Transmembrane protein 86B (TMEM86B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane protein 86B (TMEM86B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call